PYC - Ticker AI Digest

Physiomics Plc 📰 1
Desk Snapshot GO VIP Login
Important AI Risk Notice

Charts, catalyst summaries, AI scores, forecasts and price context are AI-driven and can hallucinate, lag or miss market-changing information.

Not investment advice. Markets can move fast and any trade or allocation decision remains your responsibility.
AI can hallucinate. Summaries, rankings, forecasts and commentary can be wrong, incomplete or misleading.
AI-driven data only. Signals, dates, prices, sentiment and automation outputs may be delayed, estimated or stale.
Always verify externally. Confirm prices, filings, broker notes and trade setup details with independent sources before acting.
Mobile Command Deck
Physiomics Plc in one cleaner mobile flow.
Tap straight into the module you want. No sideways tab hunt, just a clean route into charts, news, Today’s AI, and the deeper desks.
PYC Data 2025-12-11 Preview Mode
Core Deck
Deep Dive Modules

Digested News

Today's Catalysts (PYC) 1
PYC 06:01
Physiomics Plc
Physiomics Awarded New Contract by Numab
AI Expand: Explanation + Tables
Return to today’s catalyst cards, chart beacons and AI charts.
**Summary**
Physiomics plc, a leader in mathematical modelling, data science, and biostatistics for drug development, has been awarded a new contract by its long-standing client, Numab Therapeutics AG. The project involves using modelling and simulation to support the pre-clinical development of a multi-specific antibody targeting autoimmune diseases. Physiomics will develop a mechanistic Pharmacokinetics and Pharmacodynamics (PK/PD) model to optimize dosing for preclinical and clinical studies. The project is expected to be completed within the financial year ending 2026. This contract highlights the growing importance of Model Informed Drug Development (MIDD) in the drug development lifecycle. Dr. Peter Sargent, CEO of Physiomics, expressed satisfaction with the continued collaboration with Numab Therapeutics, emphasizing support for their therapeutic antibody pipeline in oncology and autoimmune indications. Physiomics has a proven track record, having contributed to over 100 commercial projects with clients including Merck KGaA, Astellas, and CRUK. The announcement was made via the London Stock Exchanges RNS news service on December 11, 2025.
NewContract
AI 0
No items for this category on selected date.
Acquisitions 0
No items for this category on selected date.
Agreement 0
No items for this category on selected date.
Approvals 0
No items for this category on selected date.
Authorisation 0
No items for this category on selected date.
Awards 0
No items for this category on selected date.
BTC 0
No items for this category on selected date.
Blockchain 0
No items for this category on selected date.
Breakthrough 0
No items for this category on selected date.
BuyBack 0
No items for this category on selected date.
Cancellations 0
No items for this category on selected date.
CashOffer 0
No items for this category on selected date.
Collaborate 0
No items for this category on selected date.
ContractWin 0
No items for this category on selected date.
Covid-19 0
No items for this category on selected date.
Deals 0
No items for this category on selected date.
Diamond 0
No items for this category on selected date.
DirectorDealing 0
No items for this category on selected date.
Discovery 0
No items for this category on selected date.
Exceeded 0
No items for this category on selected date.
FCA 0
No items for this category on selected date.
FDA 0
No items for this category on selected date.
Grants 0
No items for this category on selected date.
InvestmentPlan 0
No items for this category on selected date.
JV 0
No items for this category on selected date.
Launch 0
No items for this category on selected date.
Litigation 0
No items for this category on selected date.
NewContract 3
PYC 06:01
Physiomics Plc
Physiomics Awarded New Contract by Numab
AI Expand: Explanation + Tables
Return to today’s catalyst cards, chart beacons and AI charts.
**Summary**
Physiomics plc, a leader in mathematical modelling, data science, and biostatistics for drug development, has been awarded a new contract by its long-standing client, Numab Therapeutics AG. The project involves using modelling and simulation to support the pre-clinical development of a multi-specific antibody targeting autoimmune diseases. Physiomics will develop a mechanistic Pharmacokinetics and Pharmacodynamics (PK/PD) model to optimize dosing for preclinical and clinical studies. The project is expected to be completed within the financial year ending 2026. This contract highlights the growing importance of Model Informed Drug Development (MIDD) in the drug development lifecycle. Dr. Peter Sargent, CEO of Physiomics, expressed satisfaction with the continued collaboration with Numab Therapeutics, emphasizing support for their therapeutic antibody pipeline in oncology and autoimmune indications. Physiomics has a proven track record, having contributed to over 100 commercial projects with clients including Merck KGaA, Astellas, and CRUK. The announcement was made via the London Stock Exchanges RNS news service on December 11, 2025.
NewContract
PYC 06:01
Physiomics Plc
Physiomics Awarded New Contract by GARDP
AI Expand: Explanation + Tables
Return to today’s catalyst cards, chart beacons and AI charts.
**Summary**
Physiomics plc, a leader in mathematical modelling, data science, and biostatistics, has been awarded a new contract by the GARDP Foundation, a not-for-profit organization focused on developing new antibiotic treatments. The contract involves providing expert consultancy to optimize the design of an efficacy trial for GARDPs Serious Bacterial Infections (SBIs) program. The project, set to begin in January 2026 and complete within three months, marks Physiomics second major client in its Biometrics department and its third Biometrics contract since launching the service line earlier in 2025. This partnership expands Physiomics expertise into the infectious disease therapeutic area, aligning with the companys growth objectives. CEO Dr. Peter Sargent highlighted the contract as a significant milestone, surpassing initial projections and underscoring the potential of the Biometrics service line. Physiomics continues to support biotech and pharma companies in de-risking drug development through advanced computational tools and data-driven insights.
NewContract
PYC 06:01
Physiomics Plc
Physiomics Awarded Two New Contracts
AI Expand: Explanation + Tables
Return to today’s catalyst cards, chart beacons and AI charts.
**Summary**
Physiomics plc, a leader in mathematical modelling, data science, and biostatistics for therapeutic development, announced the award of two new contracts totaling £29,750. The first contract, valued at £13,600, extends a partnership with a UK-based AI-driven biotech firm, utilizing Physiomics Virtual Tumour Platform to guide dosing for an oncology drug. The second contract, worth £16,150, involves collaborating with a partner to support a UK biotech client in renal disease therapy development through modelling and simulation strategies. Both projects are expected to complete within a month. Dr. Peter Sargent, CEO, highlighted the significance of these contracts in demonstrating repeat business and expanding the companys therapeutic reach beyond oncology. Physiomics continues to leverage its expertise and proprietary technologies to support over 100 commercial projects with clients like Merck KGaA, Astellas, and CRUK.
**Key Points**
Two new contracts awardedtotaling £29750.
Contract 1£13,600 for oncology drug dosing with an existing client.
Contract 2£16,150 for renal disease therapy development with a new client.
Both projects to complete within a month.
Highlights repeat business and diversification into new therapeutic areas.
Physiomics supports over 100 commercial projects with cutting-edge technologies.
NewContract
Offers 0
No items for this category on selected date.
Offtake 0
No items for this category on selected date.
Orders 0
No items for this category on selected date.
Partner 0
No items for this category on selected date.
Patents 0
No items for this category on selected date.
Placing 0
No items for this category on selected date.
Positive 0
No items for this category on selected date.
Proposals 0
No items for this category on selected date.
Reports 0
No items for this category on selected date.
Results 0
No items for this category on selected date.
Significant 0
No items for this category on selected date.
Speculation 0
No items for this category on selected date.
Strategic 0
No items for this category on selected date.
Suspension 0
No items for this category on selected date.
TR1 1
PYC 15:32
Physiomics Plc
Holding(s) in Company
AI Expand: Explanation + Tables
Return to today’s catalyst cards, chart beacons and AI charts.
TR1 Buy
Takeover 0
No items for this category on selected date.
Understanding 0
No items for this category on selected date.
Updates 0
No items for this category on selected date.
Vaccine 0
No items for this category on selected date.
Wins 0
No items for this category on selected date.
Worth 0
No items for this category on selected date.
All Market News (Last 30 Days) 6
PYC 06:01
Physiomics Plc
Physiomics Awarded New Contract by Numab
AI Expand: Explanation + Tables
Return to today’s catalyst cards, chart beacons and AI charts.
**Summary**
Physiomics plc, a leader in mathematical modelling, data science, and biostatistics for drug development, has been awarded a new contract by its long-standing client, Numab Therapeutics AG. The project involves using modelling and simulation to support the pre-clinical development of a multi-specific antibody targeting autoimmune diseases. Physiomics will develop a mechanistic Pharmacokinetics and Pharmacodynamics (PK/PD) model to optimize dosing for preclinical and clinical studies. The project is expected to be completed within the financial year ending 2026. This contract highlights the growing importance of Model Informed Drug Development (MIDD) in the drug development lifecycle. Dr. Peter Sargent, CEO of Physiomics, expressed satisfaction with the continued collaboration with Numab Therapeutics, emphasizing support for their therapeutic antibody pipeline in oncology and autoimmune indications. Physiomics has a proven track record, having contributed to over 100 commercial projects with clients including Merck KGaA, Astellas, and CRUK. The announcement was made via the London Stock Exchanges RNS news service on December 11, 2025.
NewContract
PYC 06:01
Physiomics Plc
Physiomics Awarded New Contract by GARDP
AI Expand: Explanation + Tables
Return to today’s catalyst cards, chart beacons and AI charts.
**Summary**
Physiomics plc, a leader in mathematical modelling, data science, and biostatistics, has been awarded a new contract by the GARDP Foundation, a not-for-profit organization focused on developing new antibiotic treatments. The contract involves providing expert consultancy to optimize the design of an efficacy trial for GARDPs Serious Bacterial Infections (SBIs) program. The project, set to begin in January 2026 and complete within three months, marks Physiomics second major client in its Biometrics department and its third Biometrics contract since launching the service line earlier in 2025. This partnership expands Physiomics expertise into the infectious disease therapeutic area, aligning with the companys growth objectives. CEO Dr. Peter Sargent highlighted the contract as a significant milestone, surpassing initial projections and underscoring the potential of the Biometrics service line. Physiomics continues to support biotech and pharma companies in de-risking drug development through advanced computational tools and data-driven insights.
NewContract
PYC 15:32
Physiomics Plc
Holding(s) in Company
AI Expand: Explanation + Tables
Return to today’s catalyst cards, chart beacons and AI charts.
TR1 Buy
PYC 06:01
Physiomics Plc
Physiomics Awarded Two New Contracts
AI Expand: Explanation + Tables
Return to today’s catalyst cards, chart beacons and AI charts.
**Summary**
Physiomics plc, a leader in mathematical modelling, data science, and biostatistics for therapeutic development, announced the award of two new contracts totaling £29,750. The first contract, valued at £13,600, extends a partnership with a UK-based AI-driven biotech firm, utilizing Physiomics Virtual Tumour Platform to guide dosing for an oncology drug. The second contract, worth £16,150, involves collaborating with a partner to support a UK biotech client in renal disease therapy development through modelling and simulation strategies. Both projects are expected to complete within a month. Dr. Peter Sargent, CEO, highlighted the significance of these contracts in demonstrating repeat business and expanding the companys therapeutic reach beyond oncology. Physiomics continues to leverage its expertise and proprietary technologies to support over 100 commercial projects with clients like Merck KGaA, Astellas, and CRUK.
**Key Points**
Two new contracts awardedtotaling £29750.
Contract 1£13,600 for oncology drug dosing with an existing client.
Contract 2£16,150 for renal disease therapy development with a new client.
Both projects to complete within a month.
Highlights repeat business and diversification into new therapeutic areas.
Physiomics supports over 100 commercial projects with cutting-edge technologies.
NewContract
PYC 06:01
Physiomics Plc
Board Changes
PYC 14:44
Physiomics Plc
Result of AGM

Today's AI

Today's AI Starts With News

1 live catalyst is opening Today’s AI for PYC.

Start with the live headline tape first. Today’s AI findings sit next, and the AI Blend stack drops lower once the news context is framed. Financial Forecastist now feeds the blend too.
Live Tape Data 2025-12-11 Blend Lower Down
Read the alert tape first, then open Today’s AI findings. Use AI Expand on any card to open the AI explanation, results tables and financial forecast rows instantly.
1 Today
Front Of Desk
Physiomics Plc has fresh news flow live now, so Today’s AI is leading with the tape before the blended signal stack below.
Single-Ticker Today's AI
PYC signal theatre built from scored market catalysts, automated AI forecasts, financial forecasting and live trigger logic.

This is the ticker-specific Today’s AI desk for Physiomics Plc. It compresses the live catalyst tape, bullish and bearish scoring, AI price forecasts, financial forecasting and trigger logic into one cockpit so users can judge conviction without hopping across screens.

Subscription Required Bullish vs Bearish Scoring AI + Financial Blend Buy / Sell Trigger Engine Today's AI Findings
Create Account Member Login
Subscriber Unlock
Subscribe to unlock the full PYC Today’s AI cockpit.

Subscription turns this tab into a live signal desk with today’s news findings at the top, AI plus financial blend comparisons at the bottom, buy and sell trigger logic, and the full findings ledger behind every scored row.

  • AI-scored market headlines with sentiment buckets and buzzword breakdowns.
  • Forecast leaders ranked by projected gain against current market price.
  • Advanced technical scans, AI forecast stacks, and predictive MACD inside the live stock terminal charts.
  • Single-ticker AI Crunch desks with buy or sell trigger logic and full catalyst ledgers.
  • Scored earnings shock board with predicted direction, sector pulse and catalyst narrative.
  • Fast market scan built for event-driven trading, not passive dashboards.
Subscribe to unlock the ticker-specific Today’s AI stack, sentiment gauges, AI blend stage, and the full findings ledger for PYC on 2025-12-11.

Fundamentals Matrix

Overall Fundamentals
Signal: Pending
Capital Strength
Signal: Pending
Float Liquidity
Signal: Pending
Short Pressure
Signal: Pending
Target Setup
Signal: Pending
Market Profile
Signal: Pending
Market Cap
3.2M
Enterprise Value
1.7M
Public Float
46.9
Broker Target
0.2
Shares Out
453.2M
Long Interest
0
Short Interest
0
Exchange
LSE
Currency Code
GBX
ISIN
GB00BDR6W943
Market
LSE - AIM
Sector
Medical Equipment and Services
Float / Shares Ratio
-
Short vs Long Delta
-
EV / Market Cap
-

Financials Matrix

News And Alerts First

1 live alert now opens the financials desk for PYC.

Start with the headline flow and alert tape first. Then drop straight into Financial Forecastist below for the revenue path, EPS shape, cash pressure and balance-sheet read while the catalyst context is still hot.
Live Alerts Data 2025-12-11 Forecastist Below
Read the alert tape first, then move into Financial Forecastist below. Use AI Expand on any catalyst card to open the AI explanation and results tables without losing the ticker context.
1 Alerts
Front Of Desk
Physiomics Plc has fresh filing flow live now, so the tape is framing the revenue, leverage and valuation story below.
Overall Stability
Signal: Pending
Profitability
Signal: Pending
Debt & Cash
Signal: Pending
Valuation Risk
Signal: Pending
Forward Expectation
Signal: Pending
Dividend Safety
Signal: Pending
Divi Rate
-
Ex Divi
2009-01-01
Earnings Date
2026-03-04
Net Debt
-461.2K
Cash
461.2K
EPS
-
Net Income
-415.3K
Revenue
784.0K
Enterprise Value
1.7M
Trailing PE
-
Forward PE
6.1652
Price Sales TTM
3.1468
Price Book MRQ
8.0724
EV Revenue
3.0592
EV EBITDA
-8.7624
Financial Forecastist

Mixed financial engine

Revenue is accelerating +30.4% against the prior comparable period. Net margin is compressing by 6.5 pts. Net debt is coming down +32.4%.

Revenue +30.4% Net Income +46.1% FCF -42.2% Current Ratio 3.30x Forward Rev 0
Mixed
Quarter Revenue
498.0K
+30.4%
vs prior comparable quarter
Net Margin
-60.4%
-6.5 pts
profitability pulse
Free Cash Flow
-204.0K
-42.2%
cash conversion
Net Debt / EBITDA
0.7x
-32.4%
lower is cleaner
Revenue Engine

Latest quarter printed 498.0K with the top line pushing higher against the last comparable period.

Profit Stack

Net income landed at -301.0K and the margin profile is tightening. That usually tells us whether operating leverage is finally kicking in.

Balance-Sheet Pressure

Cash sits near 257.0K while net debt is -257.0K. The leverage stack is cleaning up.

Quarterly Revenue Runway

Actual revenue bars, consensus revenue where available, plus the terminal model path.

Profit And Cash Conversion

Net income and free cash flow moving together is usually what separates genuine improvement from noise.

Balance-Sheet Pressure

Cash, net debt and liquidity tell us whether the business is strengthening or just surviving.

Annual Power Curve

Longer-cycle revenue and net income help frame whether the company is compounding or rolling over.
Q4 2023
Consensus
0
Revenue Path
0.00
EPS / Earnings
Growth cue -
Q1 2024
Consensus
0
Revenue Path
0.00
EPS / Earnings
Growth cue -
Q3 2024
Consensus
0
Revenue Path
0.00
EPS / Earnings
Growth cue -
Q4 2024
Consensus
0
Revenue Path
0.00
EPS / Earnings
Growth cue -
FY 2026
Consensus
1.0M
Revenue Path
-0.00
EPS / Earnings
Growth cue +0.4%
FY 2027
Consensus
0
Revenue Path
-
EPS / Earnings
Growth cue -

Quarterly Statement Tape

Last 6 Quarters
Period Revenue Net Income FCF Net Debt
Q4 2025 498.0K -301.0K -204.0K -257.0K
Q2 2025 455.0K -184.3K -265.1K -461.2K
Q4 2024 329.0K -231.0K -285.0K -269.0K
Q2 2024 188.6K -403.4K -212.4K -191.1K
Q4 2023 382.0K -206.0K -353.0K -380.0K
Q2 2023 259.4K -245.3K -81.5K -416.6K

Annual Financial Power

Last 5 Years
Period Revenue Net Income EBITDA FCF
FY 2025 784.0K -415.3K -448.2K -550.1K
FY 2024 543.2K -609.4K -659.8K -565.4K
FY 2023 597.4K -477.3K -561.6K -271.5K
FY 2022 830.3K -253.1K -347.8K -358.6K
FY 2021 702.3K -215.8K -324.5K -48.6K

Structure DNA

Market Structure DNA

Balanced Structure profile with trend mixed

Price is 42.5% through the 52-week range, +1.1% vs 50DMA and +15.3% vs 200DMA. 23.9% of the register is locked by institutions and insiders, leaving 76.1% free float. Capital rhythm reads no cadence with forward yield near 0.0% and payout around 0.0%.

Trend mixed Institutional gravity Moderate income rhythm As Of 2026-04-19
Balanced Structure
Structure Score
53.7 / 100
Balanced Structure
Trend Stack
+1.1% / +15.3%
vs 50DMA / 200DMA
52W Position
42.5%
auction position inside the yearly range
Ownership Lock
23.9%
120.1% institutions | 22.7% insiders
Pressure Pocket
76.1% free float
Vendor short-float fields were not supplied
Capital Rhythm
No cadence
Yield 0.0% | payout 0.0%
Trend Runway

Implied spot is 0.48 with the stock +1.1% vs 50DMA and +15.3% vs 200DMA. The tape is sitting 42.5% through the 52-week range, which frames the regime as trend mixed.

Ownership Register

Institutions hold about 120.1% and insiders about 22.7%, locking roughly 23.9% of the register and leaving 76.1% in free float. That reads as institutional gravity.

Pressure Pocket

The API did not return a usable short-float field for this ticker, so the pressure score leans more on float lock and crowding than a full short ledger.

Capital Rhythm

Dividend cadence reads no cadence with - event(s) in the last full year, a five-year average of -, and stability score 0.0/100. Forward yield sits near 0.0% while payout is around 0.0%.

Structure Score

One-glance gauge for the current market-structure regime.

Pillar Radar

Trend, ownership, pressure, and capital rhythm mapped on one wheel.

Position And Float Balance

Shows whether the stock is extended, tightly held, or carrying capital-return support.

Dividend Cadence Tape

Historical dividend-event counts help reveal how dependable the income rhythm has been.

Dividend Cadence Ledger

No cadence
Year Dividend Count Context
Dividend history has not been normalized yet.

Structure Facts

Live Snapshot
Implied Spot
0.48
derived from market cap / shares
52W High
0.80
upper auction edge
52W Low
0.25
lower auction edge
Beta
0.92
volatility character
Shares Out
453.2M
fully diluted count
Shares Float
218.1M
tradable register
Shares Short
0
borrowed stock
Short Ratio
0.0x
days-to-cover style read
Ex-Dividend
-
next ex-date not supplied
Dividend Pay
-
payment date not supplied
Last Split
1:100
2016-12-19

Capital Radar

Capital Regime
—
Building signal blend...
Smart Money Tilt
—
Public vs institutions
Target Conviction
—
Broker coverage pulse
Insider Pressure
—
Director + TR1 flow
Last Held Position
-
Public Hands
-
Institutions
22.153
Institutions As Of
2026-05-26
Avg Broker Target
-
Upside Vs Price
-
Purchase Director Dealing
1
Sale Director Dealing
0
Purchase TR1
3
Sale TR1
4
Broker Coverage Rows
0
Institution Holders Tracked
5
Public Vs Institutional Ownership (3D)
Top Institution Holders (Latest Per Holder)
Director Dealing Sentiment Flow
Broker Target Bias
Signal: Pending
Capital Momentum Matrix
Broker Targets Vs Price
Aggregated Institution Weight By Holder

Short Data - Last 30 Days

Nexus Pulse Engine

Overall Buy/Sell/Hold
Signal: Pending
Technical Composite
Signal: Pending
Financial Composite
Signal: Pending
Fundamental Composite
Signal: Pending
Short Pressure
Signal: Pending
Momentum Bias
Signal: Pending

Volatility Lab

ATR(14)
Realized Vol (20d)
Volume Spike Z

AI Charts

News And Alerts First

The alert tape opens the door for PYC, and AI Charts sits just below.

Start with the headline flow and live catalyst tape first. Then move straight into AI Charts below for price reaction, AI targets, chart structure and catalyst beacons while the news context is still hot.
Live Tape Data 2025-12-11 AI Charts Below
Read the alert tape first, then move into AI Charts below. Use AI Expand on any catalyst card to open the AI explanation and results tables instantly.
1 Today
Catalyst Pulse
Physiomics Plc has fresh news flow live now, so the tape is framing the chart workspace below.
AI Charts Studio
PYC Price History
Live structure, automated forecasts, technical overlays and catalyst beacons in one chart workspace.
30 Day View Window 30D Data 2025-12-11 Open Preview Studio Brief
Chart Intelligence Suite
Swipe the timeframe, call the overlays, and keep the AI signal stack fused into one chart cockpit.
The mobile chart console is now framed as one connected surface so forecasting, structure, catalyst beacons and chart tools all sit inside the price workspace.

Automated signalling scans momentum shifts, crossovers and volatility breaks in real time. Automated AI forecasts map best, average and worst simulation paths forward, predictive MACD extends the momentum story, and catalyst beacons pin market-moving headlines directly onto price action so users can connect news, signals and structure without leaving the chart.

Automated Signalling Automated AI Forecasts Predictive MACD Catalyst Beacons Live Price Structure
Desk Snapshot Member Login
Indicators0
Technicals0
AI Forecast 103.45%
RSI Gauge
Price Change
AI Forecast